Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Khanu Management GmbH, a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG, based in Dortmund, Germany.
New facilities expand services offering to Irish and International customers
Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.
Satsuma Pharmaceuticals, Inc. has announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $82.5 million, before the underwriting discounts and commissions.
Lundbeck announced the acquisition aimed at eptinezumab, Alder’s investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide that has been submitted to the U.S. Food and Drug Administration for potential approval.
Days after reaching a tentative agreement with a majority of states involved in litigation against the company over its role in the opioid crisis in the United States, Purdue Pharmaceuticals filed Chapter 11 bankruptcy.
SpringWorks Therapeutics, Inc. announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00 per share.
Baxter International Inc., a leading global medical products company, has entered into a definitive agreement to acquire Cheetah Medical, an Israel-based leading provider of non-invasive hemodynamic monitoring technologies with offices in Boston, Massachusetts as well as Tel Aviv, as detailed in the company press release.
Biocrates Life Sciences AG, one of the world’s leading biotech companies in the field of metabolomics, is strategically realigning.
Shares of 10X Genomics surged more than 35% on its first day of trading to close at $52.75, well above its $39 initial price offering starting point.